Kate Haviland Biography and Net Worth

President, CEO & Director of Blueprint Medicines

Kate brings an impressive breadth of experience and leadership within the biopharmaceutical industry, as well as a substantial background in business development, commercial and strategic planning, and program management. She has served as a member of the board of directors for Fulcrum Therapeutics since June 2018. Kate previously served as Chief Business Officer of Blueprint Medicines from January 2016 to January 2019. Prior to joining Blueprint Medicines, she served as Vice President, Rare Diseases and Oncology Program Leadership at Idera Pharmaceuticals. In this role, she oversaw all aspects of the product development strategy for Idera Pharmaceuticals’ rare disease and oncology pipeline programs, including preclinical research, manufacturing and drug supply, regulatory affairs, clinical development and execution and commercial planning. Prior to joining Idera Pharmaceuticals, Kate was Head of Commercial Development at Sarepta Therapeutics, where she was responsible for product development and commercial planning and for cultivating relationships with key opinion leaders and patient advocacy groups. In addition, Kate previously served as Executive Director of Commercial Development at PTC Therapeutics and held corporate development and project management roles at Genzyme. She holds a B.A. from Wesleyan University with a double major in Biochemistry/Molecular Biology and Economics and an M.B.A. from Harvard Business School.

What is Kate Haviland's net worth?: The estimated net worth of Kate Haviland is at least $13.90 million as of January 21st, 2025. Ms. Haviland owns 149,378 shares of Blueprint Medicines stock worth more than $13,904,104 as of March 26th. This net worth approximation does not reflect any other assets that Ms. Haviland may own. Learn More about Kate Haviland's net worth.
How do I contact Kate Haviland?: The corporate mailing address for Ms. Haviland and other Blueprint Medicines executives is 45 SIDNEY STREET, CAMBRIDGE MA, 02139. Blueprint Medicines can also be reached via phone at (617) 374-7580 and via email at ir@blueprintmedicines.com. Learn More on Kate Haviland's contact information.
Has Kate Haviland been buying or selling shares of Blueprint Medicines?: During the past quarter, Kate Haviland has sold $159,407.04 of Blueprint Medicines stock. Most recently, Kate Haviland sold 1,446 shares of the business's stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $110.24, for a transaction totalling $159,407.04. Following the completion of the sale, the chief executive officer now directly owns 149,378 shares of the company's stock, valued at $16,467,430.72. Learn More on Kate Haviland's trading history.
Who are Blueprint Medicines' active insiders?: Blueprint Medicines' insider roster includes Jeffrey Albers (CEO), Percy Carter (Insider), George Demetri (Director), Debra Durso-Bumpus (Insider), Mark Goldberg (Director), Kate Haviland (President, CEO & Director), L. Hewes (Insider), Ariel Hurley (Insider), Michael Landsittel (CFO), Philina Lee (Insider), Nicholas Lydon (Director), Tracey Mccain (EVP), Christopher Murray (Insider), Fouad Namouni (Insider), Christina Rossi (Insider), and Charles Rowland, Jr. (Director). Learn More on Blueprint Medicines' active insiders.
Are insiders buying or selling shares of Blueprint Medicines?: In the last twelve months, insiders at the biotechnology company sold shares 23 times. They sold a total of 245,498 shares worth more than $24,943,972.10. The most recent insider tranaction occured on March, 3rd when insider Ariel Hurley sold 3,203 shares worth more than $296,661.86. Insiders at Blueprint Medicines own 4.2% of the company. Learn More about insider trades at Blueprint Medicines.
Information on this page was last updated on 3/3/2025.

Kate Haviland Insider Trading History at Blueprint Medicines

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/21/2025	Sell	1,446	$110.24	$159,407.04	149,378
11/29/2024	Sell	2,353	$96.60	$227,299.80	150,824
3/7/2024	Sell	12,464	$90.69	$1,130,360.16	153,177
3/6/2023	Sell	6,640	$45.69	$303,381.60	125,641
11/3/2022	Buy	1,100	$43.98	$48,378.00	92,281
12/13/2021	Sell	1,000	$98.30	$98,300.00
6/28/2021	Sell	1,000	$90.24	$90,240.00	54,948
10/16/2020	Sell	13,334	$101.23	$1,349,800.82	56,172
9/22/2020	Sell	3,143	$85.49	$268,695.07	45,981
1/10/2020	Sell	7,763	$85.16	$661,097.08	23,628
8/19/2019	Sell	95	$85.00	$8,075.00	15,960
7/16/2019	Sell	1,571	$95.47	$149,983.37	17,436
6/17/2019	Sell	11,952	$96.46	$1,152,889.92	12,160
3/1/2019	Sell	21,644	$85.05	$1,840,822.20	20,018
2/12/2018	Sell	6,775	$74.93	$507,650.75	12,649
10/5/2017	Sell	5,449	$66.44	$362,031.56
9/18/2017	Sell	6,356	$60.03	$381,550.68	6,356
7/5/2017	Sell	7,265	$54.66	$397,104.90	7,265
6/28/2017	Sell	6,357	$50.00	$317,850.00	6,357

Kate Haviland Buying and Selling Activity at Blueprint Medicines

Blueprint Medicines Company Overview

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $91.37

$91.40

$92.89

50 Day Range

MA: $99.12

$86.69

$115.63

2 Week Range

Now: $91.37

$80.68

$121.90

Volume

186,557 shs

Average Volume

710,483 shs

Market Capitalization

$5.84 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.58